Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00506129 · OUTCOME

Average Overall Survival (OS) Length

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma · Source last updated 2020-12-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Days
Interval / dispersion
Full Range
Time frame
Baseline to disease progression, followed up to 5 years post transplant

What was measured

OS was defined as the time from transplantation to the date of death from any cause or last follow up, measured in days.

Analysis population: Baseline to disease progression, followed up to 5 years post transplant (assess at 100 days, every 3 months for 2 years, then once a year for at least 3 years)

Groups in this outcome

Fludarabine + Melphalan With PBPC

Fludarabine 25 mg/m\^2 intravenous (IV) daily for 5 days prior to allogeneic peripheral blood progenitor cell (PBPC) , Melphalan 70 mg/m\^2 IV daily for 2 days prior to IV Allogeneic Transplant following Fludarabine \& Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 \& -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Fludarabine + Melphalan With PBPC33

Reported measurements

Source class 1
Values in Days · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Fludarabine + Melphalan With PBPC1207Not reported171825Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        17
        upper Limit
        1825
        value
        1207
denoms
  1. counts
    1. group Id
      OG000
      value
      33
    units
    Participants
description
OS was defined as the time from transplantation to the date of death from any cause or last follow up, measured in days.
dispersion Type
Full Range
groups
  1. description
    Fludarabine 25 mg/m\^2 intravenous (IV) daily for 5 days prior to allogeneic peripheral blood progenitor cell (PBPC) , Melphalan 70 mg/m\^2 IV daily for 2 days prior to IV Allogeneic Transplant following Fludarabine \& Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 \& -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
    id
    OG000
    title
    Fludarabine + Melphalan With PBPC
param Type
MEAN
population Description
Baseline to disease progression, followed up to 5 years post transplant (assess at 100 days, every 3 months for 2 years, then once a year for at least 3 years)
reporting Status
POSTED
time Frame
Baseline to disease progression, followed up to 5 years post transplant
title
Average Overall Survival (OS) Length
type
SECONDARY
unit Of Measure
Days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice